JP2020513754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513754A5 JP2020513754A5 JP2019533579A JP2019533579A JP2020513754A5 JP 2020513754 A5 JP2020513754 A5 JP 2020513754A5 JP 2019533579 A JP2019533579 A JP 2019533579A JP 2019533579 A JP2019533579 A JP 2019533579A JP 2020513754 A5 JP2020513754 A5 JP 2020513754A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- tcr
- composition according
- subunit
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022158356A JP2022188163A (ja) | 2016-12-21 | 2022-09-30 | がん治療用に操作されたｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437524P | 2016-12-21 | 2016-12-21 | |
| US62/437,524 | 2016-12-21 | ||
| PCT/US2017/068002 WO2018119298A1 (en) | 2016-12-21 | 2017-12-21 | Engineered t cells for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158356A Division JP2022188163A (ja) | 2016-12-21 | 2022-09-30 | がん治療用に操作されたｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020513754A JP2020513754A (ja) | 2020-05-21 |
| JP2020513754A5 true JP2020513754A5 (https=) | 2021-02-04 |
Family
ID=61132892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533579A Pending JP2020513754A (ja) | 2016-12-21 | 2017-12-21 | がん治療用に操作されたｔ細胞 |
| JP2022158356A Pending JP2022188163A (ja) | 2016-12-21 | 2022-09-30 | がん治療用に操作されたｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158356A Pending JP2022188163A (ja) | 2016-12-21 | 2022-09-30 | がん治療用に操作されたｔ細胞 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210187022A1 (https=) |
| EP (1) | EP3558348A1 (https=) |
| JP (2) | JP2020513754A (https=) |
| CN (1) | CN110234343A (https=) |
| AU (1) | AU2017382902A1 (https=) |
| CA (1) | CA3047999A1 (https=) |
| WO (1) | WO2018119298A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| JP7538601B2 (ja) | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| EP3615574A4 (en) | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| AU2019222560B2 (en) | 2018-02-17 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| MX2020009371A (es) * | 2018-03-09 | 2021-01-08 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. |
| KR20210069048A (ko) * | 2018-08-30 | 2021-06-10 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 재프로그래밍을 위한 조성물 및 방법 |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| WO2020201527A1 (en) | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| WO2021035170A1 (en) * | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2022002984A (es) * | 2019-09-12 | 2022-06-16 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. |
| WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2023091910A1 (en) | 2021-11-16 | 2023-05-25 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2023108150A1 (en) | 2021-12-10 | 2023-06-15 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2023133424A2 (en) * | 2022-01-05 | 2023-07-13 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014134412A1 (en) | 2013-03-01 | 2014-09-04 | Regents Of The University Of Minnesota | Talen-based gene correction |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| IL297773B2 (en) * | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| PL3298033T5 (pl) * | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| DK3909972T5 (da) * | 2015-06-19 | 2024-08-05 | Sebastian Kobold | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin |
| CA3032498A1 (en) * | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
-
2017
- 2017-12-21 JP JP2019533579A patent/JP2020513754A/ja active Pending
- 2017-12-21 WO PCT/US2017/068002 patent/WO2018119298A1/en not_active Ceased
- 2017-12-21 CN CN201780085200.3A patent/CN110234343A/zh active Pending
- 2017-12-21 US US16/472,751 patent/US20210187022A1/en not_active Abandoned
- 2017-12-21 AU AU2017382902A patent/AU2017382902A1/en not_active Abandoned
- 2017-12-21 EP EP17837926.9A patent/EP3558348A1/en not_active Withdrawn
- 2017-12-21 CA CA3047999A patent/CA3047999A1/en active Pending
-
2022
- 2022-09-30 JP JP2022158356A patent/JP2022188163A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513754A5 (https=) | ||
| JP2021087455A5 (https=) | ||
| JP2020114264A5 (https=) | ||
| JP2022113880A5 (https=) | ||
| JP2017524367A5 (https=) | ||
| JP2020513829A5 (https=) | ||
| JP2021094037A5 (https=) | ||
| JP2019527557A5 (https=) | ||
| JP2020529841A5 (https=) | ||
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2018508219A5 (https=) | ||
| AU2019288733A1 (en) | Chimeric transmembrane proteins and uses thereof | |
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2017522879A5 (https=) | ||
| JP2020511136A5 (https=) | ||
| JP2020525536A5 (https=) | ||
| JP2020517295A5 (https=) | ||
| JP2020529970A5 (https=) | ||
| JP2018532407A5 (https=) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| US11725053B2 (en) | Chimeric antigen receptors comprising a human transferrin epitope sequence | |
| JP2016514457A5 (https=) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi |